166 related articles for article (PubMed ID: 8304965)
1. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity.
De La Cruz JP; Ortega G; Sánchez de la Cuesta F
Biochem Pharmacol; 1994 Jan; 47(2):209-15. PubMed ID: 8304965
[TBL] [Abstract][Full Text] [Related]
2. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
De La Cruz JP; Moreno A; Mérida F; García Campos J; Sánchez de la Cuesta F
Thromb Res; 1996 Feb; 81(3):327-37. PubMed ID: 8928090
[TBL] [Abstract][Full Text] [Related]
3. The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
de la Cruz JP; Moreno A; Mérida F; García-Campos J; Sánchez de la Cuesta F
Pharmacol Toxicol; 1994 Nov; 75(5):250-4. PubMed ID: 7870694
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
Dawicki DD; Agarwal KC; Parks RE
Thromb Res; 1986 Jul; 43(2):161-75. PubMed ID: 3016942
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
6. Effect of dipyridamole on prostaglandin generation by human platelets and vessel walls.
Mehta J; Mehta P; Hay D
Prostaglandins; 1982 Dec; 24(6):751-61. PubMed ID: 6820166
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue.
De la Cruz JP; Olveira C; Gonzalez-Correa JA; Benítez A; Sánchez de la Cuesta F
Gen Pharmacol; 1996 Jul; 27(5):855-9. PubMed ID: 8842690
[TBL] [Abstract][Full Text] [Related]
8. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Agarwal KC; Buckley RS; Parks RE
Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
[TBL] [Abstract][Full Text] [Related]
9. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine.
Dawicki DD; Agarwal KC; Parks RE
Biochem Pharmacol; 1985 Nov; 34(22):3965-72. PubMed ID: 4062970
[TBL] [Abstract][Full Text] [Related]
10. The pyrimido-pyrimidine derivative RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes.
Bellido I; de la Cruz JP; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1991; 13(6):371-5. PubMed ID: 1881198
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity.
Zingarelli B; Southan GJ; Gilad E; O'Connor M; Salzman AL; Szabó C
Br J Pharmacol; 1997 Feb; 120(3):357-66. PubMed ID: 9031736
[TBL] [Abstract][Full Text] [Related]
12. The role of prostacyclin in vascular tissue.
Moncada S; Vane JR
Fed Proc; 1979 Jan; 38(1):66-71. PubMed ID: 215463
[TBL] [Abstract][Full Text] [Related]
13. Dipyridamole potentiates the inhibition of platelet aggregation by aspirin (in human platelet rich plasma and whole blood).
Violi F; Praticò D; Iuliano L; Balsano F
J Lipid Mediat; 1991; 4(1):61-7. PubMed ID: 1909906
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ferrous-induced lipid peroxidation by pyrimido-pyrimidine derivatives in human liver membranes.
de la Cruz JP; Carrasco T; Ortega G; Sanchez de la Cuesta F
Lipids; 1992 Mar; 27(3):192-4. PubMed ID: 1522764
[TBL] [Abstract][Full Text] [Related]
15. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of fetal vascular prostacyclin and platelet thromboxane synthesis by nonsteroidal anti-inflammatory drugs in humans.
Mäkilä UM; Kokkonen E; Viinikka L; Ylikorkala O
Prostaglandins; 1983 Jan; 25(1):39-46. PubMed ID: 6405453
[TBL] [Abstract][Full Text] [Related]
17. Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechansim of inhibition of platelet function.
McElroy FA; Philip RB
Life Sci; 1975 Nov; 17(9):1479-93. PubMed ID: 173959
[No Abstract] [Full Text] [Related]
18. Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues.
Boulos C; Jiang H; Balazy M
J Pharmacol Exp Ther; 2000 Apr; 293(1):222-9. PubMed ID: 10734173
[TBL] [Abstract][Full Text] [Related]
19. Effect of chronic low dose aspirin on platelet and vascular eicosanoid metabolism in nonhuman primates (Macaca fascicularis).
Jakubowski JA; Bush HL; Vaillancourt R; Deykin D
Arteriosclerosis; 1987; 7(6):599-604. PubMed ID: 3120680
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
